Codexis Inc. Stock
Codexis Inc. Stock
Pros and Cons of Codexis Inc. in the next few years
Pros
Cons
Performance of Codexis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Codexis Inc. | -0.700% | 0.099% | -30.980% | -75.379% | -27.969% | -80.537% | -95.294% |
| Biocryst Pharmaceuticals | 0.730% | 10.691% | 9.843% | -28.227% | -3.661% | -31.355% | -31.452% |
| Heron Therapeutics Inc. | 0.970% | 4.317% | -18.079% | -38.448% | -8.887% | -60.071% | -93.265% |
| Madrigal Pharmaceuticals inc. | -2.070% | -5.401% | -12.810% | 14.854% | -25.858% | 33.913% | 265.760% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.In general, Codexis (CDXS) appears to be a company focused on research and development and faces financial challenges typical for a biotechnology and medical research organization. While the revenues and assets are growing, the company has experienced consistent net income losses. However, Codexis maintains a strong cash position, providing a safety net to help fund its ongoing research activities.
Growing revenues: Over the past three years, the total revenue for Codexis has been increasing. In 2020, the company earned $69.05 million, which increased to $104.75 million in 2021, and further rose to $138.59 million by the end of 2022. This consistent growth is a positive sign for the company's potential future profitability.
Strong cash position: Cash is vital for a biotechnology company, as research and development efforts can be both costly and uncertain. Codexis has a solid cash position, from $149.11 million in 2020 to $116.79 million in 2021, and $102.83 million in Q1 2023. This provides the company with a financial cushion for ongoing operations and research projects.
Comments
